Inhibition of plaque formation by myxoma and fibroma viruses with pyrimidine analogues.
D000998:Antiviral Agents / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D001973:Bromodeoxyuridine / Q000494:pharmacology*; D046508:Culture Techniques; D003596:Cytosine / Q000494:pharmacology*; D004279:DNA, Viral / Q000096:biosynthesis; D005350:Fibroma; D005467:Floxuridine / Q000494:pharmacology*; D005472:Fluorouracil / Q000494:pharmacology*; D007065:Idoxuridine / Q000494:pharmacology*; D015122:Mercaptopurine / Q000494:pharmacology*; D008727:Methotrexate / Q000494:pharmacology*; D009233:Myxoma virus; D009705:Nucleosides / Q000494:pharmacology*; D009858:Oncogenic Viruses; D013882:Thiosemicarbazones / Q000494:pharmacology*; D013941:Thymine / Q000494:pharmacology*
D000998:Antiviral Agents; D001562:Benzimidazoles; D004279:DNA, Viral; D009705:Nucleosides; D013882:Thiosemicarbazones; D005467:Floxuridine; D003596:Cytosine; D015122:Mercaptopurine; D001973:Bromodeoxyuridine; D007065:Idoxuridine; D013941:Thymine; D005472:Fluorouracil; D008727:Methotrexate